Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by Trippedstockson Aug 30, 2021 12:52pm
206 Views
Post# 33781983

RE:RE:BS - why Phase 3 Bucillamine not included !

RE:RE:BS - why Phase 3 Bucillamine not included !
I forgot to post this here:

Buy out? Do people even read!?

Commercialization Rights!

MF said it. "The Company is in discussions with reputable international pharmaceutical companies seeking to obtain commercial rights to Bucillamine as a treatment for COVID-19 in various countries in Europe, India and Asia"

I don't know what the deals' $ or % numbers will be but I would expect a similar format to this:

US$20 million on signing. 50 percent on the first US$200 million in annual net sales, then 40 percent on the next US$200 million, then 35 percent on net sales greater than US$400 million. This would be about $250mill per year per deal. Add a few deals and we'd be a multi-billion $ company in no time. Let's say 4 hemispheres. That's a Billion Cash a year! Plus deals can include further R and D costs.

That is just the format. Not the exact numbers to expect.
<< Previous
Bullboard Posts
Next >>